The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Open accessAbstract
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine–induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1RAs have demonstrated considerable therapeutic promise in animal models of both PD and AD.427–429”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to its effects on metabolic regulation, GLP-1, when synthesized within the brain, exhibits neuroprotective properties.397,427,431”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 10×
“These and other actions are mediated through the G protein-coupled GLP-1R, and Ex-4 has demonstrated therapeutic value in T2DM (7).”
BackgroundMethodInfluentialDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundJavitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263 · cited 2×
“Administration of MPTP in mice induces a consistent dopaminergic cell loss that parallels many aspects of PD (16,20).”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 3×
“Although T2DM now occurs more often in the young, the incidence rises dramatically with age, along with that of many of other conditions, including acute and chronic neurologic disorders, exemplified by stroke (2), Parkinson’s disease (PD) and Alzheimer’s disease (AD) (3,4), which, like T2DM, were once considered rela…”
BackgroundD'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
BackgroundResultInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
BackgroundSelf-citationCell death in the nervous system
Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006) · Nature · doi:10.1038/nature05293 · Cited by 636 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
Background
Research works printed but not linked: 2
- R Sicree, J Shaw, P Zimmet Diabetes Atlas, ed D Gan (International Diabetes Federation, 3rd Ed, Brussels), pp. 15–103 (2006).
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Consistent with this, exendin-4 increases survival and levels of tyrosine hydroxylase, the key enzyme for dopamine production, in primary neuronal cultures treated with the dopaminergic toxin 6-hydroxydopamine (6-OHDA) [843].”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Ex-4 (21 ng, i.c.v.) given 15min prior to middle cerebral artery occlusion (MCAO) reduced infarct size in wild-type but not in Glp1r / mice (Li et al., 2009).”
BackgroundMethodInfluentialHallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Self-citationBlock of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
“GLP-1R agonists are protective in models of stroke, traumatic brain injury (TBI), AD, and the MPTP intoxication model of PD 4,5,8,12,13 .”
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Metadata
- Authors
- Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., Brossi, A., Lahiri, D. K., Mattson, M. P., Hoffer, B. J., Wang, Y., & Greig, N. H.
- Affiliations
- National Institute on Aging (US)
- Medical University of South Carolina (US)
- National Institute on Drug Abuse (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University School of Medicine (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-01-27
- Volume
- 106
- Issue
- 4
- Pages
- 1285-1290
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2633544
- OpenAlex
- W2080785707
- Cited by
- 589
- References
- 45
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 39 · 2023: 24 · 2022: 33 · 2021: 49 · 2020: 41 · 2019: 40 · 2018: 43 · 2017: 34 · 2016: 41 · 2015: 45 · 2014: 34 · 2013: 33 · 2012: 27
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- University of Toronto
- National Institutes of Health
- National Institute on Aging
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- GLP-1 receptor, exendin-4, stroke, Parkinson's disease, dopaminergic neurons, cortical neurons, neuroprotection, MPTP mouse model, middle cerebral artery occlusion, 6-hydroxydopamine, hypoxia, oxidative stress, dopamine levels, motor function
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Cells, Cultured, Cerebral Cortex, Disease Models, Animal, Dopamine, Embryo, Mammalian, Gene Expression Regulation, Humans, Mesencephalon, Neurons, Parkinson Disease, Peptides, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Hypoxia, Treatment Outcome, Cell Death, Receptors, Glucagon, Cytoprotection, Brain Infarction, Stroke, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. https://app.cochat.ai/papers/10.1073/pnas.0806720106
- The paper
- Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., Brossi, A., Lahiri, D. K., Mattson, M. P., Hoffer, B. J., Wang, Y., & Greig, N. H. (2009). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0806720106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.